Peer-reviewed veterinary case report
Higher dose vinblastine chemo for dogs with mast cell tumors safety
By Vickery, K R et al.·Published in Veterinary and comparative oncology·2008·Colorado State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Dose-escalating vinblastine for the treatment of canine mast cell tumour.
- Species:
- dog
Plain-English summary
A group of dogs with mast cell tumors (a type of skin cancer) were treated with a chemotherapy drug called vinblastine, starting at a low dose and increasing it weekly. Most dogs tolerated the lower doses well, with only a few experiencing serious side effects like low white blood cell counts and vomiting. One dog needed to be hospitalized due to these effects, but overall, the higher doses seemed safe. This suggests that using a higher dose of vinblastine could be a viable option for treating mast cell tumors in dogs, but more research is needed to see if it improves treatment outcomes.
People also search for: dog mast cell tumor treatment · vinblastine side effects in dogs · chemotherapy for dog cancer
Abstract
The purpose of this study was to evaluate the short-term adverse events (AEs) in dogs with mast cell tumours (MCT) receiving prednisone and dose-escalating vinblastine (VBL). Twenty-four dogs were treated with intravenous VBL starting at 2 mg m(-2) and then escalating in weekly increments to 2.33, 2.67 and 3 mg m(-2). AEs were graded using a standardized scoring system. No dogs receiving 2 or 2.33 mg m(-2) experienced grade 3 or 4 AEs. Among the dogs, 9.5 and 5.9% had grade 3 or 4 AEs at dosages of 2.67 and 3 mg m(-2), respectively. Serious AEs included neutropaenia (n = 3) and vomiting (n = 1), only one of which required hospitalization. These data indicate that VBL chemotherapy may be safe to administer at higher than the traditional 2 mg m(-2) dosage for dogs with MCT. Randomized prospective trials are necessary to establish whether dose escalation will translate into improved response rates when compared with the standard 2 mg m(-2) dosage.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19178670/